Table 3.
Comparison of the laboratory data (pre- and post therapy) between SLE patients with gastric mucosal injury and those without gastric mucosal injury
| Gastric mucosal injury (+) N = 11 | Gastric mucosal injury (−) N = 56 | p value | |
|---|---|---|---|
| Pre-therapy data | |||
| Gastric pH | 3.2 ± 1.7 | 3.1 ± 1.5 | 0.962 |
| Serum gastrin (pg ml−1) | 69.4 ± 30.3 | 88.5 ± 51.4 | 0.237 |
| Serum pepsinogen I (ng ml−1) | 110.9 ± 32.8 | 118.3 ± 50.3 | 0.639 |
| Serum TXB2 (pg ml−1) (COX-1 activity) | 20 195 ± 32 555 | 33 291 ± 42 143 | 0.334 |
| Serum PGE2 (pg ml−1) (COX-2 activity) | 385.3 ± 183.9 | 450.8 ± 210.6 | 0.498 |
| Gastric TXB2 (ng mg−1 protein) | 637.6 ± 643.5 | 1 525.8 ± 1 223.2 | 0.006 |
| Gastric PGE2 (ng mg−1 protein) | 288.3 ± 258.5 | 660.9 ± 551.2 | 0.004 |
| Post-therapy data | |||
| Gastric pH | 3.8 ± 2.1 | 3.0 ± 1.6 | 0.273 |
| Serum gastrin (pg ml−1) | 69.6 ± 36.0 | 89.9 ± 59.9 | 0.284 |
| Serum pepsinogen I (ng ml−1) | 113.8 ± 32.4 | 121.0 ± 52.8 | 0.662 |
| Serum TXB2 (pg ml−1) (COX-1 activity) | 18 169 ± 34 073 | 34 644 ± 41 877 | 0.178 |
| Serum PGE2 (pg ml−1) (COX-2 activity) | 356.6 ± 201.4 | 420.7 ± 209.8 | 0.310 |
| Gastric TXB2 (ng mg−1 protein) | 506.2 ± 591.8 | 1 670.0 ± 1 329.6 | <0.001 |
| Gastric PGE2 (ng mg−1 protein) | 253.5 ± 281.8 | 766.7 ± 574.2 | 0.001 |
SLE, systemic lupus erythematous; TXB2, thromboxane B2; COX, cyclooxygenase; PGE2, prostaglandin E2. Data are expressed as means ± SD.